bioAffinity Technologies, Inc. (BIAF)vsIQVIA Holdings Inc (IQV)
BIAF
bioAffinity Technologies, Inc.
$7.93
-0.25%
HEALTHCARE · Cap: $4.78M
IQV
IQVIA Holdings Inc
$261.77
+1.74%
HEALTHCARE · Cap: $42.24B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 287699% more annual revenue ($16.98B vs $5.90M). IQV leads profitability with a 8.1% profit margin vs -257.3%. IQV earns a higher WallStSmart Score of 55/100 (C).
BIAF
Avoid34
out of 100
Grade: F
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIAF.
Margin of Safety
+11.9%
Fair Value
$201.21
Current Price
$261.77
$60.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
19.0% revenue growth
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -433.7% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BIAF
The strongest argument for BIAF centers on Price/Book, Revenue Growth. Revenue growth of 19.0% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : BIAF
The primary concerns for BIAF are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
BIAF profiles as a growth stock while IQV is a value play — different risk/reward profiles.
IQV carries more volatility with a beta of 1.19 — expect wider price swings.
BIAF is growing revenue faster at 19.0% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
bioAffinity Technologies, Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
Visit Website →IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?